AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — Q1 2012 Earnings Presentation

20 slides from AMAG Pharmaceuticals's earnings presentation, May 1, 2012

  1. Slide 1: 1Q 2012 Financial Results

    1Q 2012 Financial Results May 1, 2012 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to: the pot

  3. Slide 3: Agenda

    Agenda Topic Speaker Introduction and Overview Frank Thomas, interim CEO Feraheme US CKD Business Broad IDA Opportunity John Tucker, VP of Commercial Operations Financial Highlights and Outlook Scott Holmes, VP of Finance Closing Remarks Frank Thomas, interim CEO

  4. Slide 4: Frank Thomas, Chief Operating Officer and Interim CEO

    FRANK THOMAS, CHIEF OPERATING OFFICER AND INTERIM CEO 4

  5. Slide 5: Leveraging Core Assets to Create Long-term Stockholder Value

    Leveraging Core Assets to Create Long-term Stockholder Value 5 Working with advisors to evaluate all strategic options to enhance stockholder value and leverage AMAG’s core assets Reigniting top-line growth of Feraheme with realigned expense structure ensures our balance sheet remains strong

  6. Slide 6: 2012 Year-to-Date Highlights

    US CKD business returns to growth Record Feraheme provider demand in 1Q12 40% period-over-period non-dialysis provider demand growth 10% sequential quarter growth Feraheme growth exceeded market growth tenfold International expansion milestones Canadian launch planned by Takeda in 2Q12; triggers $3

  7. Slide 7: Feraheme US CKD Business

    FERAHEME US CKD BUSINESS JOHN TUCKER, VP COMMERCIAL OPERATIONS

  8. Slide 8: 1Q12 – Record-Breaking Quarter for Feraheme

    8 1Q12 – Record-Breaking Quarter for Feraheme -Historic results based on IMS Health data. Feraheme Grams Record non-dialysis provider demand 40% period-over-period growth 10% sequential quarter growth Average weekly customers topped 700 for the first time since launch Average weekly demand topped 2,

  9. Slide 9: Increasing Demand and Share in Two Largest Market Segments

    Increasing Demand and Share in Two Largest Market Segments Source: IMS Monthly Data. 9 Feraheme in Hematology/Oncology Segment Feraheme in Hospital Segment Market Data Hematology/Oncology Segment ~206,000 IV iron grams in 2011 ~26% of total non-dialysis IV iron use Expect market growth of 7% (’12/’1

  10. Slide 10: 2012 Commercial Priorities

    2012 Commercial Priorities Implement targeted account call plan for sales representatives Feraheme segmentation messaging and patient profiling for all target audiences Leverage relationships with hematology/oncology GPOs to drive access in hard to see accounts and build awareness of Feraheme and th

  11. Slide 11: Feraheme — On Track to Meet Forecasted Growth

    11 Feraheme — On Track to Meet Forecasted Growth -Historic results based on IMS Monthly Data, IMS Weekly Data and Wholesaler Shipment Data. Feraheme Grams ~40% Growth in Feraheme Provider Demand from 2010 - 2011 >15% Growth in Feraheme Provider Demand Estimated from 2011 - 2012

  12. Slide 12: Broad IDA Opportunity

    BROAD IDA OPPORTUNITY JOHN TUCKER, VP COMMERCIAL OPERATIONS

  13. Slide 13: Two-Step Approach to Capturing Broad IDA Market with Expanded Label

    Source: IMS Health DDD Data MAT Dec11 and AMAG company estimates. IV Iron Grams CKD1 CKD1 IDA Treated Today1 CKD1 IDA Potential1 Two-Step Approach to Capturing Broad IDA Market with Expanded Label Step One: Take Share IDA Treated Today1 ~$600 million assuming a 5% increase in IV iron treatment rates

  14. Slide 14: Financial Overview

    FINANCIAL OVERVIEW SCOTT HOLMES, VP OF FINANCE 14

  15. Slide 15: First Quarter Financial Highlights

    First Quarter Financial Highlights ($ in millions, except per share ) 1Q-2012 1Q-2011 Total Revenues $15.3 $13.4 Net Feraheme Product Revenues 13.6 10.9 Cost of Product Sales 2.6 3.0 R&D Expenses 12.5 13.6 SG&A Expenses 13.2 19.6 Net Loss (12.4) (22.3) Loss Per Share (0.58) (1.05) 15 Balance Sheet $

  16. Slide 16: Strong Financial Profile

    Strong Financial Profile 16 GAAP Revenue Operating Expenses (excluding COGS) ($ in millions) ($ in millions) $53 – $57 million in Feraheme net product revenue >15% growth in grams $33 million of cash milestones to be received COGS assumed to be 14-18% of net product sales $90 – $95 million in total

  17. Slide 17: Closing Remarks

    CLOSING REMARKS FRANK THOMAS, CHIEF OPERATING OFFICER AND INTERIM CEO 17

  18. Slide 18: Focus on Performance During Time of Uncertainty

    Focus on Performance During Time of Uncertainty 18

  19. Slide 19: AMAG: Well Positioned for Growth in 2012 and Beyond

    AMAG: Well Positioned for Growth in 2012 and Beyond Clinical and regulatory Complete enrollment of broad IDA phase 3 registration program Regulatory decisions in international markets on CKD filings Positive opinion received from EMA Present/publish IDA program data IDA-302 achieved both primary eff

  20. Slide 20: Q&A

    Q&A 20 INVESTOR RELATIONS CONTACT: 617-498-3303

Amag Pharmaceuticals — Q1 2012 Earnings Presentation on 6ix